SAB Biotherapeutics, Inc. (SABS): auditor change — Auditor MHM declines re-election as SAB Biotherapeutics' independent auditor; going concern noted

SAB Biotherapeutics, Inc.

MHM notified SAB Biotherapeutics on July 25, 2023 it will not stand for re-election as auditor for FY 2023.
MHM to cease as auditor by earlier of new firm engagement, Q2 2023 10-Q filing, or August 21, 2023.
MHM's audit reports for 2021-2022 included a going concern explanatory paragraph and a material weakness in internal controls leading to a restatement.
Company is in process of selecting a new independent registered public accounting firm; no successor named yet.
MHM furnished a letter to the SEC (Exhibit 16.1) agreeing with the company's statements in this 8-K.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Mayer Hoffman McCann P.C. resigned as auditor of SAB Biotherapeutics, Inc..

Action: resignation
Auditor: Mayer Hoffman McCann P.C.

Exact text from the filing

On July 25, 2023, Mayer Hoffman McCann P.C. (“MHM”) informed SAB Biotherapeutics, Inc. (the “Company”) and the Audit Committee of the Company’s Board of Directors that it would not stand for re-election as the Company’s independent registered public accounting firm for the audit of the Company’s financial statements for the fiscal year ending December 31, 2023.

View on SEC.gov

Browse all auditor changes →

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-021186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.